Aadi Bioscience, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$39.6M
Doctors Paid
583
Transactions
2,682
2024 Total
$21.2M
Payment Breakdown by Category
Research$38.8M (97.9%)
Consulting$342,321 (0.9%)
Food & Beverage$51,210 (0.1%)
Travel$29,303 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $38.8M | 1,512 | 97.9% |
| Honoraria | $366,675 | 141 | 0.9% |
| Consulting Fee | $342,321 | 82 | 0.9% |
| Food and Beverage | $51,210 | 827 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $42,305 | 19 | 0.1% |
| Travel and Lodging | $29,303 | 66 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $14,000 | 4 | 0.0% |
| Education | $5,024 | 31 | 0.0% |
Payments by Type
Research
$38.8M
1,508 transactions
General
$850,838
1,170 transactions
Ownership
$0
4 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/_TSC2 Genes (PRECISION 1) | $14.9M | 0 | 51 |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1TSC2 Genes PRECISION 1 | $7.1M | 0 | 31 |
| Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer | $6.3M | 0 | 327 |
| A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes | $3.7M | 2 | 467 |
| A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes. | $2.7M | 1 | 271 |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors NETs of the Gastrointestinal Tract Lung or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | $2.5M | 0 | 4 |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract Lung or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | $494,611 | 0 | 315 |
| Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment | $475,934 | 0 | 23 |
| A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions | $294,203 | 0 | 2 |
| Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas | $218,068 | 0 | 8 |
| A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa | $58,869 | 0 | 5 |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | $38,440 | 0 | 4 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Caley Castelein, M.d, M.D | General Practice | Miami Beach, FL | $196,581 | $0 |
| Dr. Kamlesh Sankhala, M.d, M.D | Medical Oncology | Beverly Hills, CA | $116,500 | $0 |
| Dr. George Demetri, Md, MD | Medical Oncology | Boston, MA | $102,099 | $0 |
| Thomas Herzog, M.d, M.D | Gynecologic Oncology | Cincinnati, OH | $32,453 | $0 |
| Dr. Arun Singh, M.d, M.D | Hematology & Oncology | Santa Monica, CA | $26,261 | $0 |
| Martee Hensley, Md, MD | Medical Oncology | New York, NY | $17,759 | $0 |
| Kathleen Moore, Md, MD | Obstetrics & Gynecology | Oklahoma City, OK | $14,690 | $0 |
| David Palchak, M.d, M.D | Hematology & Oncology | Arroyo Grande, CA | $13,265 | $0 |
| Andrew Wagner, M.d, M.D | Hematology & Oncology | Boston, MA | $12,086 | $0 |
| David Kwiatkowski, Md, MD | Medical Oncology | Boston, MA | $11,965 | $0 |
| Mark Agulnik, Md, MD | Medical Oncology | Los Angeles, CA | $11,434 | $0 |
| Erlinda Gordon, Md, MD | Pediatric Hematology-Oncology | Santa Monica, CA | $10,423 | $0 |
| Dr. Lee Cranmer, Md, Phd, MD, PHD | Medical Oncology | Seattle, WA | $10,290 | $0 |
| Bradley Monk, Md, MD | Gynecologic Oncology | West Palm Beach, FL | $10,122 | $0 |
| Dr. Brian Slomovitz, M.d, M.D | Gynecologic Oncology | Fort Lauderdale, FL | $9,874 | $0 |
| William Tap, Md, MD | Hematology & Oncology | New York, NY | $7,965 | $0 |
| Richard Riedel, Md, MD | Internal Medicine | Durham, NC | $7,028 | $0 |
| Pamela Soliman, M.d, M.D | Gynecologic Oncology | Houston, TX | $6,017 | $0 |
| Marcia Brose, Md, MD | Otolaryngology | Philadelphia, PA | $5,781 | $0 |
| Robert Coleman, M.d, M.D | Gynecologic Oncology | Houston, TX | $5,738 | $0 |
| Dr. Matthew Powell, Md, MD | Gynecologic Oncology | Saint Louis, MO | $5,673 | $0 |
| Kathryn Green | Acute Care | Philadelphia, PA | $5,374 | $0 |
| Morgan Mount, Aprn, APRN | Family | Miami, FL | $5,363 | $0 |
| Michael Demeure, Md, MD | Surgery | Newport Beach, CA | $5,239 | $0 |
| Linda Duska, Md, MD | Obstetrics & Gynecology | Charlottesville, VA | $5,232 | $0 |
About Aadi Bioscience, Inc.
Aadi Bioscience, Inc. has made $39.6M in payments to 583 healthcare providers, recorded across 2,682 transactions in the CMS Open Payments database. In 2024, the company paid $21.2M. The top product by payment volume is FYARRO ($23.1M).
Payments were distributed across 46 medical specialties. The top specialty by payment amount is Medical Oncology ($341,757 to 68 doctors).
Payment categories include: Food & Beverage ($51,210), Consulting ($342,321), Research ($38.8M), Travel & Lodging ($29,303).
Aadi Bioscience, Inc. is associated with 3 products in the CMS Open Payments database.